L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients

Inclusion Criteria: 1. Patient's written informed consent 2. Received a single lung, bilateral lung or heart/lung transplantation between 6 weeks and 26 weeks prior to first IMP administration. 3. Male or female, 18 years of age 4. Capable of self-administration of medications 5. Capable of understanding the purpose and risk of the clinical trial 6. Received the following immunosuppressive agents and dosages for maintenance therapy: 1. Tacrolimus and 2. Mycophenolate mofetil (MMF) 1 to 3 g/day and 3. Prednisone or any other steroid therapy; tapered down 7. Female patients with childbearing potential must have a negative urine pregnancy test prior to first IMP administration. 8. Estimated life expectancy \> 6 month Exclusion Criteria: 1. Any previous episode of bronchiolitis obliterans (BO) or bronchiolitis obliterans syndrome (BOS) of grade 1 or higher 2. Any active invasive bacterial, viral or fungal infection 3. Received systemic maintenance immunosuppressive therapy other than listed in the inclusion criteria 4. Received any systemic or topical ciclosporin A within 5. Received any systemic or topical Rosuvastatin 6. Current mechanical ventilation 7. Received a lung re-transplantation 8. Pregnant or breast feeding woman 9. Has known hypersensitivity to ciclosporin A 10. Has a serum creatinine value of more than 265 µmol/L (3 mg/dL) 11. Unlikely to comply with visits, inhalation procedures or spirometric measurements 12. Receipt of an investigational drug within 4 weeks prior to first administration of IMP 13. Any co-existing medical condition that in the investigator's judgement 14. Psychiatric disorders or altered mental status 15. Patient was previously enrolled in the present clinical trial